Lucia Masarova/X
Sep 5, 2025, 12:18
Lucia Masarova Presents Results of Phase III SURPASS-ET Trial at SOHO 2025: Ropeg’s Efficacy for Essential Thrombocythemia
MPN Hub shared on X:
”CONGRESS | SOHO 2025 | POSTER
Lucia Masarova, MD Anderson Cancer Center
Presents results from the phase III SURPASS-ET trial of ropeginterferon alfa-2b (n=91) vs anagrelide (n=83) in patients with HR Essential Thrombocythemia who are resistant or intolerant to hydroxyurea.
Ropeg showed superior efficacy over anagrelide (RR, 42.9% vs 6.0%, P=0.0001) and demonstrated a favorable safety profile.”
All on Hemostasis and Thrombosis from SOHO 2025 featured in Hemostasis Today.
-
Sep 21, 2026, 15:56Anita Zaidi: Why Only 2% of Health Research and Development Goes to Women’s Conditions
-
Sep 21, 2026, 15:49Omid Khalafi: Gating Strategy and How Do We Decide Which Cells to Analyze
-
Sep 21, 2026, 15:44Levacetylleucine: A New Therapeutic Approach to Ataxia Telangiectasia
-
Sep 21, 2026, 15:40Andreas Tridimas: The Diagnostic Traps of Lipaemic Blood – Why a Normal Amylase Can Mislead You
-
Sep 21, 2026, 15:33Arsene Mekinian: Exploring Cardiac Involvement in Behçet’s Disease
-
Sep 21, 2026, 15:23Anis Mahjoubi: MRI Findings of Krukenberg Tumors
-
Sep 21, 2026, 15:08Fikreab Tesfaye Tefera: 10 Practical Take-Home Points for Diagnosing Iron Deficiency Anemia
-
Sep 21, 2026, 14:10Aswin K Mohan: Lessons from TRANSCON 2026 – Building Resilient Blood Supply Systems Before Crisis Hits
-
Sep 21, 2026, 14:00Vincent Lu: Beyond PT and aPTT – How Hemostasis Evolves Across a Lifetime